ReviewZeitschrift fur Rheumatologie2019
[Treatment algorithm for rheumatoid arthritis : According to the S2e guidelines 2018].
Review in Zeitschrift fur Rheumatologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- [Disease-related knowledge acquisition through structured patient information in rheumatoid arthritis (StruPI-RA) : First results of the StruPI-RA study in Germany].Zeitschrift fur Rheumatologie · 2021Article
- [Glucocorticoid-free and low-dose glucocorticoid treatment of rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2021Review
- JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration.International journal of molecular sciences · 2020Review
- Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every patient suffering from active rheumatoid arthritis should be treated with disease-modifying antirheumatic drugs (DMARD) but methotrexate initially remains the first choice treatment. Treatment should comply with the treat-to-target principle. The therapeutic aim is remission if attainable or at least a low disease activity. Remission is defined as a simplified disease activity score index (SDAI) of ≤3.3 or as fulfilling the so-called Boolean criteria. A first evaluation of the response is due after 12 weeks. At this time there should be a measurable response defined as an improvement of at least 50% of the composite score, e.g. the DAS28. If no improvement has been achieved, treatment should be continued with either a second DMARD strategy conventionally with synthetic DMARDs (csDMARDs) or an alternative with biological (bDMARD) or targeted synthetic (tsDMARDs) DMARD, depending on whether there are risk factors for a severe disease progression. A change within bDMARDs and tsDMARDs as well as therapeutic de-escalation are both possible measures in the further course of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.